FDA Grants Novartis Breakthrough Therapy Designation for CAR-T Cell Treatment – Bioscience Technology
Bioscience Technology |
FDA Grants Novartis Breakthrough Therapy Designation for CAR–T Cell Treatment
Bioscience Technology The investigational chimeric antigen receptor T cell (CAR-T) therapy, known as CTL019 was first developed by researchers at the University of Pennsylvania. Novartis and Penn entered into a global collaboration for development and commercialization of … CAR–T Cell Therapy Receives FDA Breakthrough Designation Novartis' (NVS) CTL109 BLA Gets Breakthrough Therapy Status 3 Things In Biotech You Should Learn Today: April 19, 2017 |
